New combo therapy aims to shrink rectal tumors faster
NCT ID NCT07669220
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a new treatment approach for high-risk rectal cancer: short-course radiation followed by immunotherapy (toripalimab) and chemotherapy (FOLFOX) versus the standard long-course chemoradiation. The goal is to see if the new approach leads to more complete tumor responses and better long-term outcomes. The trial plans to enroll 76 adults with a specific type of rectal cancer that has not spread widely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toripalimab (a PD-1 inhibitor) combined with FOLFOX chemotherapy
What this could lead to
If successful, this could offer a more effective and less toxic treatment option for high-risk rectal cancer, potentially reducing the need for major surgery.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 76 participants, so results may not apply to everyone. The combination therapy may cause significant side effects, and it's not yet proven to be better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Sixth Affiliated Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••